Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
about
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cellsDistinct ETA receptor binding mode of macitentan as determined by site directed mutagenesisRegulation of blood pressure and salt homeostasis by endothelin.Pulmonary arterial hypertension: advances in pathophysiology and management.Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1.Peroxisome Proliferator-Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling.EDN1 Gene Variant is Associated with Neonatal Persistent Pulmonary HypertensionPharmacokinetic evaluation of ambrisentan.Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy.Current strategies for treating infants with severe bronchopulmonary dysplasia.Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article.Macitentan: a review of its use in patients with pulmonary arterial hypertension.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Macitentan: entry-into-humans study with a new endothelin receptor antagonist.The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.Endothelin-1 induces VCAM-1 expression-mediated inflammation via receptor tyrosine kinases and Elk/p300 in human tracheal smooth muscle cells.Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.Segmentation features and structural organization of the intrapulmonary artery of the yak.
P2860
Q21133932-CBC054C7-A192-4912-985E-BE9EAB4CD3B5Q35256194-8542D558-F93E-4D21-8CB5-216C6F5E0EB5Q35609851-5C590EEC-012D-4217-A536-60F63108C75BQ35732584-3C0DA55D-B864-4AE6-B0D8-764D8EA73A0EQ36261523-CCD75C2E-1C54-4245-90A8-4E24C581E309Q36549041-ACBD7E52-BC2A-4A53-9D7C-228C9DFE94C1Q37101315-6F836486-2249-4431-A880-5EACDF1AAE15Q37836910-90EA4BFB-665E-49BE-9A7A-881713180832Q37893969-3C4CBE40-AC23-4517-94F4-F1DB41D193DEQ38046912-50B60C78-FD1D-4D09-9AB0-ECE8E69E7CF6Q38082752-CE9CB115-C80D-47C3-AE2A-FF8F2E407B33Q38233833-0465B0E6-2FC0-428B-A0CB-E56C3368E0E6Q38325919-4190E9D2-E5CB-4756-9781-583A0330D91DQ38362243-6661A6D9-86CA-44FD-9CCF-CD1828FD4D63Q39684983-AA851961-4D06-4467-B5DD-E514588D6E1BQ40382703-6DDB8DFB-DE39-483C-BC3D-EC95EED7FC53Q40838812-45744F99-0EF0-44AC-A0BA-EA8D65FF35DBQ47895451-A9064AC6-F425-4E86-BAAF-532EF19A5E2AQ53086659-92BB06CA-1DB0-4CB5-942A-359CC3EB99A1
P2860
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endothelin receptor antagonist ...... ationale and place in therapy.
@en
Endothelin receptor antagonist ...... ationale and place in therapy.
@nl
type
label
Endothelin receptor antagonist ...... ationale and place in therapy.
@en
Endothelin receptor antagonist ...... ationale and place in therapy.
@nl
prefLabel
Endothelin receptor antagonist ...... ationale and place in therapy.
@en
Endothelin receptor antagonist ...... ationale and place in therapy.
@nl
P1476
Endothelin receptor antagonist ...... ationale and place in therapy.
@en
P2093
Laura C Price
Luke S G E Howard
P304
P356
10.2165/00129784-200808030-00004
P577
2008-01-01T00:00:00Z
P6179
1042960158